GSK's Blujepa met primary endpoints in phase 3 trials, showing 58.5% success in EAGLE-3 vs. 43.6% for nitrofurantoin in uUTI treatment. The FDA approved Blujepa for uUTIs in female adults and ...
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years Over half of all women experience a uUTI in their lifetime, with approximately 30% suffering from a recurrent ...
University of Sydney researchers outline findings from a case study published by the American Society for Microbiology and ...
Winter often triggers recurrent UTIs in women. Here's why cold weather, dehydration, delayed urination and reduced immunity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback